SEC Filing Timeline
424B5May 26, 2026
Prospectus / offering
8-KMay 26, 2026
Material agreement · Items 1.01,8.01,9.01
8-KMay 26, 2026
Other material event · Items 8.01
424B5May 26, 2026
Prospectus / offering
8-KMay 26, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KMay 14, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
10-QMay 05, 2026
Quarterly report
8-KMay 05, 2026
Earnings release · Items 2.02,9.01
DEFA14AApr 28, 2026
Additional proxy
DEF 14AApr 28, 2026
Proxy statement
8-KApr 07, 2026
Financial exhibits · Items 4.01,9.01
8-KMar 27, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
10-KMar 09, 2026
Annual report
8-KMar 09, 2026
Earnings release · Items 2.02,9.01
Recent News (Finnhub)
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine: Resetting Pipeline Just To Be Second To Market Again
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
Which stocks are moving before the opening bell on Tuesday?
Editas Medicine Announces Proposed Public Offering
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Prima…